Ewopharma has two core business units – Rx (prescription medicine) and consumer health. Our focus is on four key therapeutic areas: 

  • gastroenterology
  • immunology
  • neurology
  • oncology 

This focus is based on the specific, unmet medical need in these therapeutic areas within our region. Over the past 60 years we have accumulated in-depth knowledge and expertise, making Ewopharma an important name in these specific fields of the pharmaceutical sector. We develop and implement successful go-to-market strategies for specialty, rare/orphan, hospital and consumer health products.


Ewopharma has an established gastroenterology portfolio built upon the cornerstone that is our partnership with Dr. Falk Pharma, which began over 20 years ago. Dr. Falk products for inflammatory and chronic gastrointestinal disorders have been part of our portfolio ever since. We are particularly proud of the successful establishment of innovative products such as Salofalk (mesazine) and Ursofalk (ursodiol) in the markets, at a time when no generic alternatives were available.
More recent and equally important additions to the gastroenterology portfolio include BioGaia probiotic products, Biogen anti-TNF biosimilars, and Pharmacosmos’ state-of-the-art intravenous iron therapies.


Our immunology franchise currently comprises therapies for inflammatory and autoimmune disorders, allergic and respiratory diseases and infectious diseases. The products here range from simple medication for coughs and colds to Ewopharma’s own immune stimulator Isoprinosine®, a non-specific immunomodulatory agent indicated as an adjunctive treatment to standard antiviral or surgical treatment for viral infections to new-generation, state-of-the-art treatments for adult patients with life-threatening, pulmonary multidrug-resistant tuberculosis.
Key licensed products in this area include Biogen Benepali (etanercept) and Flixabi (infliximab), Deltyba (delamanid) by Otsuka, Stallergènes Greer’s immunotherapy for respiratory allergies, and Mead Johnson baby formula for severe cow’s milk allergy.


Within our neurology portfolio, we focus on degenerative central nervous system (CNS) disorders and, in particular, diseases that affect the musculoskeletal apparatus. We currently market products for multiple sclerosis (MS), Parkinson’s disease (PD), spinal muscular atrophy (SMA) and epilepsy, but are looking to expand our portfolio with further treatments in this area, as well as those for rare diseases and other niche products. One breakthrough therapy we have launched in this field is Biogen Spinraza for SMA patients.


Oncology has long been dominated by large pharma companies that research, develop and market their own innovative therapies. But recently licensing opportunities have arisen for smaller indications or certain territories, complementing our strategy to bring new, much-needed treatments to the markets in Ewopharma’s target regions in Central Eastern Europe and Switzerland. 
Our partnership with Eisai forms the foundation of Ewopharma’s oncology portfolio. Ewopharma markets Eisai Halaven (eribulin mesylate) for locally advanced or metastatic breast cancer and Targretin (bexarotene) for skin manifestations of advanced-stage cutaneous T-cell lymphoma (CTCL) in adults.